PDRN vs Polynucleotides: What the Research Shows

Published on May 3, 2026 by Simon Finch | Fabian Finch

As marine-derived DNA ingredients gain popularity in the North American skincare market, a confusing terminology has emerged. Consumers encounter "PDRN" and "polynucleotides" (PN) — sometimes used interchangeably, sometimes presented as competing technologies. The distinction matters, because the biological mechanisms and clinical evidence differ meaningfully, and choosing the right ingredient depends on understanding what the research actually shows.

This article provides a clear, evidence-based comparison of PDRN versus polynucleotides, drawing on the peer-reviewed literature to help American women make informed decisions about which ingredient aligns with their skincare goals.

Defining the Terminology

Both PDRN and polynucleotides are DNA-derived compounds, but they differ in their production methods, molecular composition, and biological activity.

PDRN (Polydeoxyribonucleotide): A mixture of DNA fragments typically 50–1500 base pairs in length, extracted from salmon or trout sperm cells through a process of enzymatic digestion and purification. PDRN is characterized by its relatively low molecular weight (typically 50–300 kDa for topically optimized fractions) and its well-characterized binding affinity for the A2A adenosine receptor ^[1].

Polynucleotides (PN): A broader category encompassing longer DNA or RNA polymers. In the skincare context, PN refers to high-molecular-weight DNA fragments (typically 500–3000+ base pairs) that are also derived from salmon DNA. PN products marketed for aesthetic use tend to have a higher average molecular weight than PDRN — in some cases exceeding 1500 kDa ^[2].

Molecular Mechanism: Different Pathways, Different Effects

The molecular mechanism of PDRN is well-established. PDRN fragments of 50–300 base pairs bind specifically to the A2A adenosine receptor with a binding affinity (Ki) in the nanomolar range. This receptor binding triggers the cAMP/PKA/CREB signaling cascade, upregulating VEGF, FGF, and anti-inflammatory cytokines while downregulating pro-inflammatory mediators ^[3].

The mechanism of high-molecular-weight polynucleotides is less well-defined. Because longer DNA chains have less flexibility and may not fit as efficiently into the A2A receptor binding pocket, PN's primary mode of action appears to be different. Research suggests that PN provides nucleotide building blocks through salvage pathways — essentially donating raw materials for DNA repair — and also acts as a biomechanical hydrator, forming a protective film on the skin surface ^[4].

This difference is clinically significant. PDRN's receptor-mediated mechanism produces active cellular responses: increased proliferation, induced gene expression, and modulation of inflammatory pathways. PN's effects are primarily passive: providing nutrients and moisture, which support existing cellular function but do not actively stimulate new activity ^[5].

Clinical Evidence: Head-to-Head Comparisons

Direct comparative studies between PDRN and polynucleotides are limited but instructive. A 2023 study in the Journal of Cosmetic Dermatology compared topical formulations of low-molecular-weight PDRN (50–200 kDa) and high-molecular-weight PN (600–1200 kDa) in a randomized, double-blind trial involving 40 women aged 45–65 ^[6].

Results after 12 weeks:

• Skin elasticity: PDRN improved by 31.2% vs. PN 18.5%
• Skin hydration: PDRN improved by 27.6% vs. PN 24.1% (difference not statistically significant)
• Wrinkle depth: PDRN reduced by 21.4% vs. PN 12.8%
• Dermal thickness (ultrasound): PDRN increased by 14.2% vs. PN 6.7%

The study concluded that while both ingredients are safe and effective, PDRN produced "significantly greater improvements in parameters associated with dermal regeneration" ^[6].

A 2024 systematic review of 22 studies on DNA-derived skincare ingredients found that studies using PDRN with molecular weights under 300 kDa consistently reported positive results on collagen synthesis and dermal thickness, while studies using higher-molecular-weight fractions showed more variable outcomes ^[7].

Clinical Evidence: The Body of Research

The clinical evidence base for PDRN is substantially larger than for PN, reflecting PDRN's longer history of therapeutic use. PDRN has been studied in over 30 human clinical trials for dermatological and cosmetic applications, including 8 randomized controlled trials specifically for anti-aging. Polynucleotide research, while growing, is approximately five years behind in terms of published clinical data ^[8].

A key advantage of PDRN is its well-documented safety record derived from its medical use. PDRN has been used in clinical settings for wound healing and tissue regeneration since the 1990s, providing long-term safety data that PN cannot yet match ^[9].

Which Is Right for You?

For American women seeking maximum regenerative benefits, the research supports PDRN as the more potent option, particularly for stimulating collagen production, improving elasticity, and reducing wrinkle depth. The A2A receptor mechanism provides a level of biological activity that high-molecular-weight polynucleotides cannot reproduce.

However, polynucleotides may have their own advantages. Their larger molecular size provides a more substantial film-forming effect on the skin surface, which can be beneficial for immediate hydration and moisture barrier support. Some users also report a more pronounced immediate "plumping" effect with PN products ^[10].

At Fabian Finch, we focus on PDRN precisely because the evidence for receptor-mediated regeneration is stronger. Our formulations are optimized to the 50–300 kDa molecular weight range that maximizes A2A receptor binding while maintaining sufficient bioavailability for transdermal delivery.

European customers can shop at finchmarine.com for our complete range of marine-derived PDRN products.

References

[1] Kim, J. et al. "Characterization of polydeoxyribonucleotide from salmon milt." Marine Drugs, 2021; 19(8): 445.
[2] Lee, S.H. et al. "Polynucleotide structure and function in aesthetic medicine." Journal of Cosmetic Dermatology, 2023; 22(6): 1722–1729.
[3] Park, J. et al. "Anti-inflammatory effects of PDRN through A2A receptor activation." International Journal of Molecular Sciences, 2021; 22(15): 8124.
[4] Kwon, T.R. et al. "Mechanism of action of polynucleotides in skin rejuvenation: A review." Dermatologic Therapy, 2023; 36(5): e15315.
[5] Choi, S.Y. et al. "Comparing low-molecular-weight and high-molecular-weight DNA fragments for skin regeneration." Marine Drugs, 2022; 20(11): 703.
[6] Kim, H.Y. et al. "Randomized double-blind comparison of PDRN and polynucleotide in skin rejuvenation." Journal of Cosmetic Dermatology, 2023; 22(9): 2502–2511.
[7] Chen, W. et al. "Systematic review of marine DNA-derived ingredients in aesthetic dermatology." Clinical, Cosmetic and Investigational Dermatology, 2024; 17: 301–318.
[8] Ahn, J. et al. "Clinical evidence for DNA-derived cosmetic ingredients: A meta-analysis." Journal of Dermatological Treatment, 2024; 35(1): 238–248.
[9] Cavallini, M. et al. "Safety of PDRN in clinical use: A 20-year retrospective analysis." Journal of Plastic Dermatology, 2023; 19(2): 72–82.
[10] Lee, Y.J. et al. "Immediate film-forming and hydration effects of polynucleotide gels." Journal of Cosmetics, Dermatological Sciences and Applications, 2023; 13(3): 201–212.